The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders
- 428 Downloads
Altered production of cytokines can result in pathologies ranging from autoimmune diseases to malignancies. The Janus kinase family is a small group of receptor-associated signaling molecules that is essential to the signal cascade originating from type I and type II cytokine receptors. Inhibition of tyrosine kinase enzymatic activity using small molecules has recently become a powerful tool for treatment of several malignancies. Twenty years after the discovery of these enzymes, two inhibitors for this class of kinases have been approved for clinical use and others are currently in the final stage of development. Here we review the principles of cytokines signaling, summarize our current knowledge of the approved inhibitors, and briefly introduce some of the inhibitors that are currently under development.
KeywordsRheumatoid Arthritis Patient Herpes Zoster Polycythemia Vera Tofacitinib Ruxolitinib
We thank the following individuals for critical reading of the manuscript: Dr. Kiyoshi Hirahara, Dr. Giuseppe Sciumè, Ms. Kathryn Davis, and Dr. Jonathan Mallett.
NIAMS have a Collaborative Research Agreement and Development Agreement (CRADA) with Pfizer.
- 19.Brugnoni D, Notarangelo LD, Sottini A, Airo P, Pennacchio M, Mazzolari E, et al. Development of autologous, oligoclonal, poorly functioning T lymphocytes in a patient with autosomal recessive severe combined immunodeficiency caused by defects of the Jak3 tyrosine kinase. Blood. 1998;91(3):949–55.PubMedGoogle Scholar
- 23.Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs: Invest Drugs J. 2010;13(6):394–403.Google Scholar
- 31.Yoshida H, Kimura A, Fukaya T, Sekiya T, Morita R, Shichita T, et al. Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. Biochem Biophys Res Commun. 2012;418(2):234–40.CrossRefPubMedGoogle Scholar
- 33.van Gurp E, Weimar W, Gaston R, Brennan D, Mendez R, Pirsch J, et al. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant: Off J Am Soc Transplant Am Soc Transplant Surg. 2008;8(8):1711–8.CrossRefGoogle Scholar
- 39.van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. New Engl J Med. 2012;367(6):508–19.Google Scholar